Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Y-Mabs falls to Serb
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
